ELENI EFSTATHIOU to Neoplasms, Hormone-Dependent
This is a "connection" page, showing publications ELENI EFSTATHIOU has written about Neoplasms, Hormone-Dependent.
Connection Strength
0.293
-
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
Score: 0.103
-
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81.
Score: 0.085
-
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82.
Score: 0.084
-
Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903.
Score: 0.022